The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine

Vaccine

Volumn 27, Issue 37, 2009, Pages 5077-5084

  Liu, Jun ^a   Ngai, Nicholas ^a   Stone, Geoffrey W ^a   Yue, Feng Yun ^a   Ostrowski, Mario A ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Adjuvant; AIDS; Canarypox vector

Indexed keywords

ADJUVANT; CD134 ANTIGEN; CD40 LIGAND; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; OX40 LIGAND; UNCLASSIFIED DRUG; VCP1452 VACCINE; VIRUS VECTOR;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CANARYPOX VIRUS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENTIATION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; CANARYPOX VIRUS; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; OX40 LIGAND; SPLEEN;

EID: 67650762199     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.046     Document Type: Article

References (48)

1. Fauci A.S., Johnston M.I., Dieffenbach C.W., Burton D.R., Hammer S.M., Hoxie J.A., et al. HIV vaccine research: the way forward. Science 321 5888 (2008) 530-532
2. Letvin N.L. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 6 12 (2006) 930-939
3. Robinson H.L. HIV/AIDS vaccines: 2007. Clin Pharmacol Ther 82 6 (2007) 686-693
4. Sekaly R.P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?. J Exp Med 205 1 (2008) 7-12
5. Watts T.H. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23 (2005) 23-68
6. Sugamura K., Ishii N., and Weinberg A.D. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 4 6 (2004) 420-431
7. Rogers P.R., Song J., Gramaglia I., Killeen N., and Croft M. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 15 3 (2001) 445-455
8. Song J., Salek-Ardakani S., Rogers P.R., Cheng M., Van Parijs L., and Croft M. The costimulation-regulated duration of PKB activation controls T cell longevity. Nat Immunol 5 2 (2004) 150-158
9. Bansal-Pakala P., Halteman B.S., Cheng M.H., and Croft M. Costimulation of CD8 T cell responses by OX40. J Immunol 172 8 (2004) 4821-4825
10. Song A., Song J., Tang X., and Croft M. Cooperation between CD4 and CD8 T cells for anti-tumor activity is enhanced by OX40 signals. Eur J Immunol 37 5 (2007) 1224-1232
11. Lee S.W., Park Y., Song A., Cheroutre H., Kwon B.S., and Croft M. Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses. J Immunol 177 7 (2006) 4464-4472
12. Redmond W.L., Gough M.J., Charbonneau B., Ratliff T.L., and Weinberg A.D. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. J Immunol 179 11 (2007) 7244-7253
13. Zaini J., Andarini S., Tahara M., Saijo Y., Ishii N., Kawakami K., et al. OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice. J Clin Invest 117 11 (2007) 3330-3338
14. Serghides L., Bukczynski J., Wen T., Wang C., Routy J.P., Boulassel M.R., et al. Evaluation of OX40 ligand as a costimulator of human antiviral memory CD8 T cell responses: comparison with B7, 1 and 4-1BBL. J Immunol 175 10 (2005) 6368-6377
15. Yu Q., Yue F.Y., Gu X.X., Schwartz H., Kovacs C.M., and Ostrowski M.A. OX40 ligation of CD4+ T cells enhances virus-specific CD8+ T cell memory responses independently of IL-2 and CD4+ T regulatory cell inhibition. J Immunol 176 4 (2006) 2486-2495
16. Tartaglia J., Perkus M.E., Taylor J., Norton E.K., Audonnet J.C., Cox W.I., et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188 1 (1992) 217-232
17. Cox W.I., Tartaglia J., and Paoletti E. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology 195 2 (1993) 845-850
18. Pitisuttithum P. HIV-1 prophylactic vaccine trials in Thailand. Curr HIV Res 3 1 (2005) 17-30
19. Marovich M.A. ALVAC-HIV vaccines: clinical trial experience focusing on progress in vaccine development. Expert Rev Vaccines 3 Suppl. 4 (2004) S99-104
20. de Bruyn G., Rossini A.J., Chiu Y.L., Holman D., Elizaga M.L., Frey S.E., et al. Safety profile of recombinant canarypox HIV vaccines. Vaccine 22 5-6 (2004) 704-713
21. Liniger M., Zuniga A., and Naim H.Y. Use of viral vectors for the development of vaccines. Expert Rev Vaccines 6 2 (2007) 255-266
22. Clements-Mann M.L., Weinhold K., Matthews T.J., Graham B.S., Gorse G.J., Keefer M.C., et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 177 5 (1998) 1230-1246
23. Cleghorn F., Pape J.W., Schechter M., Bartholomew C., Sanchez J., Jack N., et al. Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120. J Acquir Immune Defic Syndr 46 2 (2007) 222-230
24. Thongcharoen P., Suriyanon V., Paris R.M., Khamboonruang C., de Souza M.S., Ratto-Kim S., et al. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr 46 1 (2007) 48-55
25. Goepfert P.A., Horton H., McElrath M.J., Gurunathan S., Ferrari G., Tomaras G.D., et al. High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis 192 7 (2005) 1249-1259
26. Liu J., Yu Q., Stone G.W., Yue F.Y., Ngai N., Jones R.B., et al. CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals. Vaccine 26 32 (2008) 4062-4072
27. Fang Z.Y., Limbach K., Tartaglia J., Hammonds J., Chen X., and Spearman P. Expression of vaccinia E3L and K3L genes by a novel recombinant canarypox HIV vaccine vector enhances HIV-1 pseudovirion production and inhibits apoptosis in human cells. Virology 291 2 (2001) 272-284
28. Lyons A.B. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods 243 1-2 (2000) 147-154
29. Huster K.M., Busch V., Schiemann M., Linkemann K., Kerksiek K.M., Wagner H., et al. Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets. Proc Natl Acad Sci U.S.A. 101 15 (2004) 5610-5615
30. Bachmann M.F., Wolint P., Schwarz K., Jager P., and Oxenius A. Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L. J Immunol 175 7 (2005) 4686-4696
31. Huster K.M., Koffler M., Stemberger C., Schiemann M., Wagner H., and Busch D.H. Unidirectional development of CD8+ central memory T cells into protective Listeria-specific effector memory T cells. Eur J Immunol 36 6 (2006) 1453-1464
32. Ruby C.E., Redmond W.L., Haley D., and Weinberg A.D. Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses. Eur J Immunol 37 1 (2007) 157-166
33. Wherry E.J., Teichgraber V., Becker T.C., Masopust D., Kaech S.M., Antia R., et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 4 3 (2003) 225-234
34. Precopio M.L., Betts M.R., Parrino J., Price D.A., Gostick E., Ambrozak D.R., et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 204 6 (2007) 1405-1416
35. Ruby C.E., Montler R., Zheng R., Shu S., and Weinberg A.D. IL-12 is required for anti-OX40-mediated CD4 T cell survival. J Immunol 180 4 (2008) 2140-2148
36. Soroosh P., Ine S., Sugamura K., and Ishii N. Differential requirements for OX40 signals on generation of effector and central memory CD4+ T cells. J Immunol 179 8 (2007) 5014-5023
37. Salek-Ardakani S., and Croft M. Regulation of CD4 T cell memory by OX40 (CD134). Vaccine 24 7 (2006) 872-883
38. Calderhead D.M., Buhlmann J.E., van den Eertwegh A.J., Claassen E., Noelle R.J., and Fell H.P. Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions. J Immunol 151 10 (1993) 5261-5271
39. Stuber E., Neurath M., Calderhead D., Fell H.P., and Strober W. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 2 5 (1995) 507-521
40. Stuber E., and Strober W. The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J Exp Med 183 3 (1996) 979-989
41. Murata K., Ishii N., Takano H., Miura S., Ndhlovu L.C., Nose M., et al. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J Exp Med 191 2 (2000) 365-374
42. Kim M.Y., Gaspal F.M., Wiggett H.E., McConnell F.M., Gulbranson-Judge A., Raykundalia C., et al. CD4(+)CD3(-) accessory cells costimulate primed CD4 T cells through OX40 and CD30 at sites where T cells collaborate with B cells. Immunity 18 5 (2003) 643-654
43. Pippig S.D., Pena-Rossi C., Long J., Godfrey W.R., Fowell D.J., Reiner S.L., et al. Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40). J Immunol 163 12 (1999) 6520-6529
44. Chen A.I., McAdam A.J., Buhlmann J.E., Scott S., Lupher Jr. M.L., Greenfield E.A., et al. Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immunity 11 6 (1999) 689-698
45. Kopf M., Ruedl C., Schmitz N., Gallimore A., Lefrang K., Ecabert B., et al. OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL responses after virus infection. Immunity 11 6 (1999) 699-708
46. Nguyen V.T., and Benveniste E.N. IL-4-activated STAT-6 inhibits IFN-gamma-induced CD40 gene expression in macrophages/microglia. J Immunol 165 11 (2000) 6235-6243
47. Lee S.J., Rossi R.J., Lee S.K., Croft M., Kwon B.S., Mittler R.S., et al. CD134 costimulation couples the CD137 pathway to induce production of supereffector CD8 T cells that become IL-7 dependent. J Immunol 179 4 (2007) 2203-2214
48. Takahashi Y., Tanaka Y., Yamashita A., Koyanagi Y., Nakamura M., and Yamamoto N. OX40 stimulation by gp34/OX40 ligand enhances productive human immunodeficiency virus type 1 infection. J Virol 75 15 (2001) 6748-6757